ArticleCancer reports (Hoboken, N.J.)2025
Potential of Serum ApoC1 as a Noninvasive Biomarker for Breast Cancer Detection and Prognosis: A Prospective Case-Control Study.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Potential of Serum ApoC1 as a Noninvasive Biomarker for Breast Cancer Detection and Prognosis: A Prospective Case-Control Study.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsBreast cancer (BC) is one of the most frequent malignancies. Apolipoprotein C1 (ApoC1) has been known as a promising therapeutic target and valuable prognostic and diagnostic biomarker in cancers. The aim of this study was to explore the diagnostic implication of serum ApoC1 concentration in new cases of BC.
methodsThis prospective case-control study was conducted on 76 new cases of BC patients referred to Amir-al-Momenin Gerash hospital. Subjects in the control group were 15 healthy individuals. The serum concentrations of ApoC1 of the control group and the BC patients were measured by ELISA assay. Data analysis was performed using Student's t-test and one-way analysis of variance (ANOVA) followed by Dunnett's post hoc test.
resultsThe mean age of the BC patients was 49.21 ± 10.42 years. In terms of diagnostic performance, ApoC1 concentration showed a significant down-regulation in female BC patients compared to healthy controls. The receiver operating characteristic (ROC) curve analysis indicated an area under the curve (AUC) of 1.00, demonstrating the excellent diagnostic value of ApoC1 in distinguishing BC patients from healthy individuals. The optimal cutoff value for ApoC1 concentration was determined to be 15.4 mg/dL, with 100% sensitivity, 100% specificity, and 100% accuracy. Furthermore, the prognostic analysis focused on HER2 over-expression patients demonstrated a statistically significant difference in ApoC1 concentration compared to other types of BC. The ROC curve analysis revealed the prognostic performance of ApoC1, with an optimal cutoff value of 5.6 mg/dL, 100% positive predictive value (PPV), and 100% negative predictive value (NPV).
conclusionAccording to the findings of the current study, ApoC1 may be a potential serum biomarker for the diagnosis of BC. Moreover, ApoC1 can be considered a highly accurate prognostic biomarker for BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.